Paid Advertisement
Session Description
Dr. Maurer, Dr. Cuddy, Dr. Grodin, and Dr. Masri will describe strategies for improving recognition of clinical clues for ATTR-CM and for making an earlier and accurate diagnosis. Evidence with disease-modifying therapies for ATTR-CM will be presented including interpretations of recently completed clinical trials and newly published analyses. Two cases with panel discussions will be presented, with a focus on avoiding pitfalls, explaining best practices to overcome management challenges, and simplifying apparent complexities of diagnosis.
Educational Objectives
- Identify suggestive findings for ATTR-CM
- Summarize the diagnostic evaluation for cardiac amyloidosis
- Interpret the evidence for ATTR-CM disease-modifying therapies
- Discuss strategies for the use of HF medications in patients diagnosed with ATTR-CM
- Explain the importance of genetic testing in the diagnosis of ATTR-CM
- Describe the challenges associated with the management of transthyretin amyloidosis
Saturday, November 7, 2026
Dinner and Registration:
5:30 PM – 6:00 PM
Symposium:
6:00 PM – 7:30 PM
McCormick Place Convention Center
Room: Industry Meeting Room, Level 4, N427D
2301 S. Dr. Martin Luther King Jr. Drive
Chicago, IL
Chair
Mathew Maurer, MD
Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
Vagelos College of Physicians & Surgeons
New York, New York
Faculty
Sarah Cuddy, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Justin Grodin, MD, MPH
Associate Professor of Medicine
Department of Internal Medicine – Division of Cardiology
University of Texas Southwestern Medical Center
Dallas, Texas
Ahmad Masri, MD, MS
Associate Professor of Medicine
Oregon Health & Science University
Portland, Oregon
Click here for more information
This event is not part of the official Scientific Sessions Conference 2026 as planned by the American Heart Association Committee on Scientific Sessions Programming.
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP and Ionis Pharmaceuticals.
This program is sponsored by
